跳至主要内容
临床试验/JPRN-UMIN000030998
JPRN-UMIN000030998已完成未知

Combination chemotherapy with methotrexate and vinblastine for surgically unresectable, aggressive desmoid tumor - Chemotherapy for desmoid

Kanazawa University Hospital0 个研究点目标入组 6 人开始时间: 2018年1月25日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
6

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
16years-old 至 85years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • contraindication for methotrexate or vinblastine, severe heart disease, renal dyfunction, respiratory failure, caogulation disorder pregnant Other medical, social, or psychological conditions that in the opinion of an investigator precludes the patient from appropriate consent

研究者

相似试验

招募中
1 期
chemotherapy for aggressive desmoid tumor
JPRN-jRCTs041180009Hayashi Katsuhiro6
已完成
不适用
ow-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumorsdesmoid
JPRN-UMIN000019337agoya University Hospital20
招募中
1 期
CO-THEIA (COMBINATION THERAPY WITH METHOTREXATE AND ADALIMUMAB FOR UVEITIS): EFFICACY, SAFETY AND COST-EFFECTIVENESS OF METHOTREXATE, ADALIMUMAB, OR THEIR COMBINATION IN NON INFECTIOUS NON ANTERIOR UVEITIS: A MULTICENTER, RANDOMIZED, PARALLEL 3 ARMS, ACTIVE-CONTROLLED, PHASE 3 OPEN LABEL WITH BLINDED OUTCOME ASSESSMENT STUDY.on-infection uveitis
CTIS2024-513123-17-00Fundacion Para La Investigacion Biomedica Del Hospital Clinico San Carlos192
已完成
4 期
IMPROVED: Induction therapy with Methotrexate and Prednisone in Rheumatoid Or Very Early arthritic Disease;A randomized clinical trial in patients with recent-onset arthritis to compare the efficacy of DMARD combination therapy including prednisone with combination therapy including adalimumab, a TNF-blocking agent.rheumatoid arthritis - rheumatic disease1000381610023213
NL-OMON30362eids Universitair Medisch Centrum610
进行中(未招募)
不适用
IMPROVED: Induction therapy with Methotrexate and Prednisone in Rheumatoid Or Very Early arthritic DiseaseA randomized clinical trial in patients with recent-onset arthritis to compare the efficacy of DMARD combination therapy including prednisone with combination therapy including adalimumab, a TNF-blocking agent - IMPROVEDrheumatoid arthritis and undifferentiated arthritisMedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
EUCTR2006-006186-16-NLeiden University Medical Center, department of rheumatology